Clinical Trial

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Name: Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL — clinical trial record (NCT07208981)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an open-label, multicenter, phase 2, non-randomized study aiming to evaluate the efficacy and safety of orelabrutinib combined with zebetuzumab and lenalidomide or bendamustine combined with rituximab in the treatment of newly diagnosed marginal zone lymphoma (MZL).

Trial Details

NCT Number	NCT07208981
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Marginal Zone Lymphoma(MZL)
Enrollment	169 participants
Start Date	2025-08-14
Primary Completion	2028-06-01 (estimated)
Study Completion	2031-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-10-06